Press Releases

Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

December 10, 2017 - Regulatory press release

Stockholm – December 10th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the first survival data were presented at the annual meeting of the American Society of Hematology from t...

Read more

Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today

December 9, 2017 - Regulatory press release

Stockholm – December 9th, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that interim data was presented at the American Society of Hematology from the ongoing phase II study HORIZON, t...

Read more

Oncopeptides AB Interim Report July – September 2017

November 15, 2017 - Regulatory press release

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the third quarter 2017 report. “The data from our study, O-12-M1, provides us with an increased degree of comfort regarding a p...

Read more

Oncopeptides to attend the Jefferies Healthcare Conference in London on November 16th

November 7, 2017 - Regulatory press release

Stockholm – November 7, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will attend Jefferies annual Healthcare Conference in London on November 16th.

Read more

Oncopeptides to present data from two clinical studies of Ygalo® (melflufen) at American Society of Hematology (ASH), December 9-12.

November 1, 2017 - Regulatory press release

Stockholm – November 1, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will present results from two clinical studies at ASH in Atlanta, US: Final data from the phase II study c...

Read more

Nomination Committee appointed in respect of AGM 2018 in Oncopeptides

October 17, 2017 - Regulatory press release

Stockholm - October 17, 2017 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on 18 May 2017, the Nomination Committee...

Read more

Oncopeptides AB Interim Report April – June 2017

August 25, 2017 - Regulatory press release

”It is gratifying that our pivotal Phase III study OCEAN commenced during the quarter, according to our strategic plan. This is a milestone for Ygalo® and for us as a company, and takes us one step cl...

Read more

First patient dosed in the pivotal phase III study OCEAN with Ygalo® (melflufen)

June 14, 2017 - Regulatory press release

Stockholm - June 14, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the first patient has been dosed in the pivotal phase III study OCEAN. The study is targeting Late-Stage Relapsed...

Read more

Bulletin from the Annual General Meeting in Oncopeptides AB (Publ)

May 18, 2017 - Regulatory press release

Stockholm, Sweden – 18 May 2017 — Oncopeptides AB’s (ONCO) annual general meeting 2017 was held today, at IVA Conference center in Stockholm. At the meeting, the following principal resolutions were passe...

Read more

Oncopeptides AB Interim Report January – March 2017

May 18, 2017 - Regulatory press release

Stockholm, Sweden – Oncopeptides AB (Nasdaq Stockholm; ONCO) today announced the first quarter 2017 report. ”Our IPO received strong interest both from Sweden and internationally, including several wel...

Read more

Change in number of shares and votes in Oncopeptides AB (publ)

April 28, 2017 - Regulatory press release

During April, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 977 906 shares and votes due to the new issue of shares...

Read more

Annual General Meeting in Oncopeptides AB (publ)

April 18, 2017 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438 (“Oncopeptides” or the “Company”), are hereby given notice to attend the Annual General Meeting to be held in the Banquet room at IVA Con...

Read more

Oncopeptides AB issues 977,906 shares additionally in connection with offer to acquire shares and listing on Nasdaq Stockholm (the “Offering”)

March 27, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

ABG Sundal Collier AB exercises the over-allotment option regarding 977,906 shares in Oncopeptides AB (publ)

March 24, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected.

March 22, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

Fourth member of Oncopeptides’ Nomination Committee appointed for the 2017 AGM

March 22, 2017 - Other press release

Stockholm - March 22, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the composition of the Nomination Committee has now been completed.

Read more

Additional patent protection for Ygalo granted in Europe until 2032

March 21, 2017 - Regulatory press release

Stockholm - March 21, 2017 - Oncopeptides AB (Nasdaq Stockholm; ONCO) announced today that the European Patent Office (EPO) recently issued a notice that they intend to grant an additional European patent...

Read more

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) that stabilisation measures regarding the Company’s shares have been effected.

March 13, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

ABG Sundal Collier AB (”ABGSC”) has notified Oncopeptides AB (publ) (“Oncopeptides” or the ”Company”) that stabilisation measures regarding the Company’s shares have been effected.

March 2, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

Change in number of shares and votes in Oncopeptides AB (publ)

February 28, 2017 - Regulatory press release

During February, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 16,786,215 shares and votes due to the new issues of shares that were made in...

Read more

Company’s CEO Acquires Shares in Oncopeptides

February 24, 2017 - Regulatory press release

Stockholm, Sweden - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the company's CEO, Jakob Lindberg acquired 45,000 shares in Oncopeptides for a value of SEK 1.9M in addition to the shares...

Read more

Trading of Oncopeptides AB (publ) on Nasdaq Stockholm commences today

February 22, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

Oncopeptides AB (publ) announces a listing of its shares on Nasdaq Stockholm

February 8, 2017 - Other press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN.

Read more

First patients are now enrolled in HORIZON, Oncopeptides’ Phase II Clinical Trial in Late Stage Relapsed and Refractory Multiple Myeloma

January 19, 2017 - Other press release

Oncopeptides AB, a clinical stage pharmaceutical company, developing the peptidase potentiated therapy Ygalo (melflufen), announced that the clinical development program is continuing according to plan....

Read more

Notice to attend an extraordinary shareholders’ meeting in Oncopeptides AB (Publ)

January 4, 2017 - Other press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, are hereby given notice to attend an extraordinary shareholders’ meeting to be held at the company’s premises on Västra Trädgårdsgatan 15 in ...

Read more